Fractyl Health, Inc. Files Amendment to S-1 Registration Statement

Ticker: GUTS · Form: S-1/A · Filed: Jan 29, 2024 · CIK: 1572616

Fractyl Health, Inc. S-1/A Filing Summary
FieldDetail
CompanyFractyl Health, Inc. (GUTS)
Form TypeS-1/A
Filed DateJan 29, 2024
Risk Levellow
Pages15
Reading Time18 min
Key Dollar Amounts$14.00, $16.00, $65 billion
Sentimentneutral

Complexity: moderate

Sentiment: neutral

Topics: Fractyl Health, S-1/A, IPO, Registration Statement, Emerging Growth Company

TL;DR

<b>Fractyl Health, Inc. has filed an amendment to its S-1 registration statement, indicating its status as an emerging growth company preparing for a public offering.</b>

AI Summary

Fractyl Health, Inc. (GUTS) filed a Amended IPO Registration (S-1/A) with the SEC on January 29, 2024. Fractyl Health, Inc. filed an amendment (S-1/A) to its registration statement on January 29, 2024. The company is incorporated in Delaware and its principal executive offices are located at 17 Hartwell Avenue, Lexington, MA 02421. The filing indicates Fractyl Health is a non-accelerated filer, smaller reporting company, and emerging growth company. The registration statement is for an offering under the Securities Act of 1933. The company was formerly known as Fractyl Laboratories Inc., with a name change on March 20, 2013.

Why It Matters

For investors and stakeholders tracking Fractyl Health, Inc., this filing contains several important signals. This S-1/A filing is a crucial step in Fractyl Health's process to become a publicly traded company, allowing it to raise capital through an IPO. The classification as an emerging growth company suggests potential benefits regarding regulatory disclosures and compliance requirements compared to larger, more established filers.

Risk Assessment

Risk Level: low — Fractyl Health, Inc. shows low risk based on this filing. The filing is an amendment to an S-1 registration statement, which is a standard procedural step for an IPO and does not contain new financial performance data or significant business updates that would alter the risk profile.

Analyst Insight

Monitor future filings for the pricing and effective date of the IPO, as well as detailed financial projections and business strategy.

Key Numbers

  • 333-276046 — SEC File Number (Registration number for the S-1 filing)
  • 27-3553477 — IRS Employer Identification No. (Tax identification number)
  • 3841 — SIC Code (Primary Standard Industrial Classification Code)

Key Players & Entities

  • Fractyl Health, Inc. (company) — Registrant name
  • 2024-01-29 (date) — Filing date
  • S-1/A (document) — Filing type
  • Delaware (jurisdiction) — State of incorporation
  • 17 Hartwell Avenue Lexington, MA 02421 (address) — Principal executive offices
  • Harith Rajagopalan, M.D., Ph.D. (person) — Chief Executive Officer
  • Fractyl Laboratories Inc. (company) — Former company name
  • 2013-03-20 (date) — Date of name change

Forward-Looking Statements

  • Fractyl Health, Inc. will complete its initial public offering (IPO) (Fractyl Health, Inc.) — medium confidence, target: Q2 2024

FAQ

When did Fractyl Health, Inc. file this S-1/A?

Fractyl Health, Inc. filed this Amended IPO Registration (S-1/A) with the SEC on January 29, 2024.

What is a S-1/A filing?

A S-1/A is a amendment to an IPO registration statement, typically incorporating SEC feedback. This particular S-1/A was filed by Fractyl Health, Inc. (GUTS).

Where can I read the original S-1/A filing from Fractyl Health, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Fractyl Health, Inc..

What are the key takeaways from Fractyl Health, Inc.'s S-1/A?

Fractyl Health, Inc. filed this S-1/A on January 29, 2024. Key takeaways: Fractyl Health, Inc. filed an amendment (S-1/A) to its registration statement on January 29, 2024.. The company is incorporated in Delaware and its principal executive offices are located at 17 Hartwell Avenue, Lexington, MA 02421.. The filing indicates Fractyl Health is a non-accelerated filer, smaller reporting company, and emerging growth company..

Is Fractyl Health, Inc. a risky investment based on this filing?

Based on this S-1/A, Fractyl Health, Inc. presents a relatively low-risk profile. The filing is an amendment to an S-1 registration statement, which is a standard procedural step for an IPO and does not contain new financial performance data or significant business updates that would alter the risk profile.

What should investors do after reading Fractyl Health, Inc.'s S-1/A?

Monitor future filings for the pricing and effective date of the IPO, as well as detailed financial projections and business strategy. The overall sentiment from this filing is neutral.

How does Fractyl Health, Inc. compare to its industry peers?

Fractyl Health operates in the medical device sector, specifically focusing on surgical and medical instruments and apparatus.

Are there regulatory concerns for Fractyl Health, Inc.?

The filing is made under the Securities Act of 1933, which governs the registration of securities offerings in the United States.

Industry Context

Fractyl Health operates in the medical device sector, specifically focusing on surgical and medical instruments and apparatus.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities offerings in the United States.

What Investors Should Do

  1. Review the full S-1 filing for detailed business operations, risk factors, and financial information.
  2. Track the SEC's review process and any subsequent amendments to the registration statement.
  3. Monitor news and analyst reports regarding Fractyl Health's IPO and market reception.

Key Dates

  • 2024-01-29: Filing of S-1/A Amendment — Indicates progress in the IPO process.
  • 2013-03-20: Name Change — Marks the transition from Fractyl Laboratories Inc. to Fractyl Health, Inc.

Year-Over-Year Comparison

This is an amendment to a previously filed S-1 registration statement, indicating procedural updates rather than a new initial filing.

Filing Stats: 4,443 words · 18 min read · ~15 pages · Grade level 15 · Accepted 2024-01-29 06:09:39

Key Financial Figures

  • $14.00 — ial public offering price to be between $14.00 and $16.00 per share. Currently, no pub
  • $16.00 — offering price to be between $14.00 and $16.00 per share. Currently, no public market
  • $65 billion — herapy. In 2022, there was an estimated $65 billion in annual pharmaceutical spending on dr

Filing Documents

RISK FACTORS

RISK FACTORS 18 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 91

USE OF PROCEEDS

USE OF PROCEEDS 93 DIVIDEND POLICY 95 CAPITALIZATION 96

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 101 A LETTER FROM OUR CO-FOUNDER 121

BUSINESS

BUSINESS 122 MANAGEMENT 198 EXECUTIVE AND DIRECTOR COMPENSATION 205 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 219 PRINCIPAL STOCKHOLDERS 221

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 225 SHARES ELIGIBLE FOR FUTURE SALE 232 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS 235

UNDERWRITING

UNDERWRITING 240 LEGAL MATTERS 249 EXPERT 249 WHERE YOU CAN FIND MORE INFORMATION 249 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS F-1 Neither we nor the underwriters have authorized anyone to provide any information or to make any representations other than those contained in this prospectus, any amendment or supplement to this prospectus, or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares of common stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside the United States : Neither we nor the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside the United States. i Table of Contents Index to Financial Statements BASIS OF PRESENTATION Except where the context otherwise requires or where otherwise indicated, the terms Fractyl, Fractyl Health, we, us, our, our company, Company and our business refer to Fractyl Health, Inc and its subsidiary. The consolidated financial statements include the accounts of Fractyl Health, Inc. Our financial statements have

View Full Filing

View this S-1/A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.